115
Participants
Start Date
December 11, 2020
Primary Completion Date
August 29, 2021
Study Completion Date
October 28, 2021
hzVSF-v13
Dosage form: 100mg / 200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1, 3, 7, D14(if necessary)
Placebo (Normal saline solution)
Dosage form: 0.9% NaCl Solution Frequency: Dose at Day 1, 3, 7, D14(if necessary)
Dipartimento di Medicina Interna, Milan
UOC Pneumologia, Bergamo
"SPb SBIH Municipal Hospital №40", Saint Petersburg
Pokrovskaya Municipal Hospita, Saint Petersburg
Regional Clinical Hospital No1, Smolensk
Central City Hospital of Novoshakhtinsk, Novoshakhtinsk
Regional Clinical Hospital, Saratov
Federal State Budgetary Educational Institution of Higher Education, Ufa
Federal Siberian Scientific and Clinical Center of the Federal Medical and Biological Agency, Krasnoyarsk
Lead Sponsor
ImmuneMed, Inc.
INDUSTRY